SeaStar Medical Stock (NASDAQ:ICU)


FinancialsChart

Previous Close

$2.04

52W Range

$1.70 - $42.92

50D Avg

$2.79

200D Avg

$8.00

Market Cap

$9.19M

Avg Vol (3M)

$203.98K

Beta

-1.06

Div Yield

-

ICU Company Profile


SeaStar Medical Holding Corporation, a medical device company, focuses on providing novel solutions and services to treat hyperinflammation and cytokine storm in critically ill patients. The company is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. It is developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure with and without LVAD; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is based in Denver, Colorado.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

12

IPO Date

Mar 18, 2021

Website

ICU Performance


ICU Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-14.21M$-11.61M$-4.45M
Net Income$-26.23M$-23.01M$-4.60M
EBITDA$-14.21M$-11.61M$-4.36M
Basic EPS$-1.21$-2.80$-0.35
Diluted EPS$-1.21$-2.80$-0.35

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
REVBRevelation Biosciences, Inc.
BDRXBiodexa Pharmaceuticals Plc
CNSPCNS Pharmaceuticals, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
IMMXImmix Biopharma, Inc.
ALLRAllarity Therapeutics, Inc.
SONNSonnet BioTherapeutics Holdings, Inc.
UNCYUnicycive Therapeutics, Inc.
PALIPalisade Bio, Inc.